Novartis PREVENT data show Cosentyx delivers early relief in axial spondyloarthritis.

Novartis announced detailed results from the Phase III PREVENT trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The ongoing trial met its primary endpoint of ASAS40 at Week 16, with 42.2% of nr-axSpA patients treated with Cosentyx 150 mg showing a significant and clinically meaningful reduction in disease activity versus placebo (42.2% vs 29.2%: p<0.05).>

Statistically significant improvements in secondary endpoints were also demonstrated, including pain, mobility and health-related quality of life. The trial showed a sustained response and a safety profile consistent with previous clinical trials. No new safety signals were detected. PREVENT data are being presented as a late-breaking abstract at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting in Atlanta, Georgia, USA.